Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
LINCOLN Stock Chart & Stats
₹496.60
-₹14.55(-1.74%)
At close: 4:00 PM EST
₹496.60
-₹14.55(-1.74%)
Day’s Range― - ―
52-Week Range₹439.95 - ₹679.45
Previous CloseN/A
Volume57.32K
Average Volume (3M)1.66K
Market Cap
₹11.10B
Enterprise Value₹10.83B
Total Cash (Recent Filing)₹2.32B
Total Debt (Recent Filing)₹668.00K
Price to Earnings (P/E)8.5
Beta1.32
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)14.28
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72
Revenue Forecast (FY)₹8.82B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthAn effectively debt-free balance sheet gives Lincoln durable financial flexibility: it can fund capex, R&D, or bolt-on deals without relying on external financing, absorb cyclical downturns with low solvency risk, and keep interest costs minimal—supporting long-term strategic optionality.
Stable Revenue GrowthConsistent top-line expansion across periods signals sustainable demand and commercial execution across domestic and export channels. Steady revenue provides scale to spread fixed costs, supports reinvestment in product development and distribution, and underpins medium-term organic growth prospects.
Improving Cash GenerationA strong rebound in free cash flow improves internal funding capacity for operations, capex and working capital, reducing reliance on borrowing. Higher FCF coverage of earnings enhances liquidity resilience and gives management choices for reinvestment or shareholder returns over the coming months.
Bears Say
Margin CompressionNoticeable margin deterioration reflects rising cost pressures or pricing challenges that reduce earnings power. Sustained margin compression can erode cash flow and ROE, constrain reinvestment capacity, and require either efficiency measures or pricing resets to restore prior profitability levels.
Cash Conversion VariabilityOperating cash consistently trailing net income and prior-year swings point to working-capital volatility. That variability makes cash planning less predictable, can strain liquidity in tighter periods, and reduces the reliability of reported profits as an indicator of available cash for investment or distributions.
Declining Return On EquityA drop in ROE signals reduced capital efficiency, potentially driven by margin erosion or a growing equity base. If the trend persists, it may limit long-term shareholder returns and suggests management must improve margins or allocate capital more effectively to restore historical returns.
Lincoln Pharmaceuticals Ltd News
LINCOLN FAQ
What was Lincoln Pharmaceuticals Ltd’s price range in the past 12 months?
Lincoln Pharmaceuticals Ltd lowest stock price was ₹439.95 and its highest was ₹679.45 in the past 12 months.
What is Lincoln Pharmaceuticals Ltd’s market cap?
Lincoln Pharmaceuticals Ltd’s market cap is ₹11.10B.
When is Lincoln Pharmaceuticals Ltd’s upcoming earnings report date?
Lincoln Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 41 days.
How were Lincoln Pharmaceuticals Ltd’s earnings last quarter?
Lincoln Pharmaceuticals Ltd released its earnings results on Feb 12, 2026. The company reported ₹14.279 earnings per share for the quarter, beating the consensus estimate of N/A by ₹14.279.
Is Lincoln Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Lincoln Pharmaceuticals Ltd’s price is currently Overvalued.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd pays a Annually dividend of ₹1.8 which represents an annual dividend yield of 0.37%. See more information on Lincoln Pharmaceuticals Ltd dividends here
What is Lincoln Pharmaceuticals Ltd’s EPS estimate?
Lincoln Pharmaceuticals Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lincoln Pharmaceuticals Ltd have?
Lincoln Pharmaceuticals Ltd has 20,029,728 shares outstanding.
What happened to Lincoln Pharmaceuticals Ltd’s price movement after its last earnings report?
Lincoln Pharmaceuticals Ltd reported an EPS of ₹14.279 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.516%.
Which hedge fund is a major shareholder of Lincoln Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:LINCOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
Technical Analysis
Kilitch Drugs (India) Limited
―
Kopran Limited
―
Themis Medicare Limited
―
Wanbury Limited
―
Anuh Pharma Limited
―